Loading...
Market
Story
US FDA Expands GSK's Jemperli Plus Chemo Approval in Endometrial Cancer
Aug 2, 2024, 11:05 AM
The US FDA has expanded the approval of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer. This marks the first and only immuno-oncology-based treatment to demonstrate an overall survival benefit for this patient group. This expanded indication, developed by GSK, is expected to significantly impact treatment protocols and patient outcomes in the field of gynecologic oncology.
View original story
Similar markets
Ease of Administration • 25%
Cost Effectiveness • 25%
Patient Preference • 25%
Clinical Effectiveness • 25%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Approved • 25%
Not Approved • 25%
Pending • 25%
Withdrawn • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%